Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
J Pediatr ; 204: 162-171.e3, 2019 01.
Article in English | MEDLINE | ID: mdl-30318371

ABSTRACT

OBJECTIVE: To assess whether treatment with biologic response modifying agents during clinical trial study periods increases the risk of serious infections in children with juvenile idiopathic arthritis (JIA). STUDY DESIGN: A systematic literature review using Medline, Embase, Cochrane library, and the clinical trial registry was performed up to July 2017. Random effects meta-analyses were used to compare rates of serious infections in children with JIA given biologic agents compared with controls, and the pooled relative risk calculated. Subanalyses were performed for different biologic agent classes. RESULTS: In total, 19 trials accounting for 21 individual studies were included (11 for tumor necrosis factor-alpha inhibitors [n = 814 patients], 3 for interleukin-6 inhibitors [n = 318], 6 for interleukin-1 inhibitors [n = 353], and 1 for selective T-lymphocyte costimulation modulators [n = 122]). Patients (68% female) had a mean age of 10.8 years. Seventeen serious infections were reported among 810 children receiving biologic agents and 15 among 797 controls. The most frequent infections were bronchopulmonary and varicella. No statistically significant difference in risk of serious infections was found between children receiving biologic agents compared with control groups (pooled relative risk = 1.13; 95% CI [0.63, 2.03]) during the trial study periods. The risk remained nonsignificant when evaluating the different classes of biologic agents separately. However, the analyses were underpowered to detect differences in the risk of serious infections overall or differences between classes of biologic agents. CONCLUSIONS: In this systematic review and meta-analyses, serious infections were uncommon and not significantly increased among patients with JIA receiving biologic agents compared with controls. However, the analyses were underpowered and study periods were relatively short. Ongoing careful monitoring for serious infections remains necessary for all patients with JIA, and particularly those receiving biologic agents.


Subject(s)
Antirheumatic Agents/adverse effects , Arthritis, Juvenile/drug therapy , Biological Products/adverse effects , Infections/chemically induced , Adolescent , Antirheumatic Agents/therapeutic use , Biological Products/therapeutic use , Child , Female , Humans , Incidence , Infections/epidemiology , Male , Risk Factors
2.
J Pediatr ; 206: 212-216, 2019 03.
Article in English | MEDLINE | ID: mdl-30466792

ABSTRACT

OBJECTIVE: To review pediatric idiopathic intervertebral disc calcification (PIIVDC) within a single center and within the literature to outline the disease course, management, and outcome. STUDY DESIGN: A retrospective chart review was performed spanning the period between January 2001 and February 2016 for diagnoses of PIIVDC. Patient age, sex, symptoms, and history and physical and neurologic findings were reviewed. Laboratory and imaging findings, management, follow-up, and outcome also were studied. RESULTS: Nine cases of PIIVDC were identified; they included 6 male and 3 female patients, with an age range of 23 months to 12 years. Two patients were asymptomatic, and PIIVDC was discovered incidentally. Of the remaining 7 patients, 5 presented with neck and/or back pain, 1 with painless torticollis, and 1 with painful torticollis. One patient reported neurologic symptoms of pain radiating along 1 dermatome. Disc spaces affected were 5 cervical, 4 thoracic, and 2 lumbar, with 2 patients having more than 1 space affected. All patients were managed conservatively. In 1 case, symptoms and lesions persisted after 5 years, but the remainder had complete symptom resolution, generally within 6 months. CONCLUSIONS: The etiology of PIIVDC remains unknown but appears to occur spontaneously, without preceding trauma or underlying medical condition. A conservative approach to patients without severe neurologic deficit with outpatient follow-up is supported.


Subject(s)
Calcinosis/diagnosis , Calcinosis/therapy , Intervertebral Disc Degeneration/diagnosis , Intervertebral Disc Degeneration/therapy , Calcinosis/complications , Child , Child, Preschool , Diagnosis, Differential , Female , Humans , Infant , Infant, Newborn , Intervertebral Disc Degeneration/complications , Male , Retrospective Studies , Risk Factors , Symptom Assessment
6.
J Pediatr ; 146(3): 395-401, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15756228

ABSTRACT

OBJECTIVE: To assess the value of spinal radiographs in determining the significance of reductions in bone mass or density in chronically ill children. STUDY DESIGN: A pediatric scoring method for assessment of osteoporotic vertebral changes, developed on the basis of radiographs of 70 healthy controls and established adult scoring methods, was subsequently used to assess 32 pediatric patients with suspected secondary osteoporosis. Radiographic findings were correlated with bone mineral density (BMD), clinical data, and biochemistry. RESULTS: Thirty-two patients (median age 14.1 years) were included. Assessment of spinal radiographs with the developed scoring method found previously undiagnosed spinal compression deformities in 11 patients (34%) of whom 9 were asymptomatic and 8 had lumbar spine (size-corrected) BMD measurements within +/-2.0 SD of the age- and sex-specific norms. Fracture history and cumulative glucocorticoid (GC) dose did not differ between those with and without compression deformities. CONCLUSIONS: Vertebral compression fractures can be documented in a significant number of chronically ill children and are poorly predicted by single BMD measurements and clinical history. Assessment of vertebral morphology is recommended as an additional tool in the diagnostic workup of pediatric osteoporosis.


Subject(s)
Osteoporosis/diagnostic imaging , Spinal Fractures/diagnostic imaging , Absorptiometry, Photon , Adolescent , Bone Density , Calcitriol/blood , Calcium/blood , Case-Control Studies , Child , Chronic Disease , Female , Glucocorticoids/adverse effects , Humans , Male , Parathyroid Hormone/blood , Regression Analysis , Spinal Fractures/etiology , Spine/diagnostic imaging
9.
J Pediatr ; 141(2): 198-203, 2002 Aug.
Article in English | MEDLINE | ID: mdl-12183714

ABSTRACT

OBJECTIVE: To determine the clinical outcomes of children with chronic recurrent multifocal osteomyelitis (CRMO). STUDY DESIGN: Inception cohorts of children with CRMO were established at two tertiary pediatric centers. Outcome data were obtained through review of hospital charts, interview and examination of patients, and completion of questionnaires by patients. RESULTS: Of 45 eligible subjects, 23 (51%) were assessed. Median time since diagnosis was 13 years (range, 6-25). At evaluation, 6 (26%) had active disease; 18 (78%) had Health Assessment Questionnaire scores of 0 (no/minimal physical disability), and 5 had scores >0. Some impairment was seen in all domains of measurement of quality-of-life test, especially those concerning nonphysical aspects of health. Six (26%) subjects continued to have pain as a result of CRMO. Associated medical problems included arthritis in 6, sacroiliitis in 3, psoriasis in 5, recurrent pustular rashes in 2, and inflammatory bowel disease in 3. CONCLUSIONS: Long-term clinical outcomes for children with CRMO appear to be generally good, with most subjects having no evidence of disease activity or sequelae. However, a number of subjects had persistent disease and, therefore, remain at risk of physical and psychologic complications. Further research is required to identify patients at risk for persistent disease, and to determine therapies that may prevent morbidity.


Subject(s)
Osteomyelitis , Adolescent , Anti-Bacterial Agents/therapeutic use , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Australia , Biopsy , Canada , Child , Child Welfare , Child, Preschool , Chronic Disease , Cohort Studies , Female , Follow-Up Studies , Humans , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/psychology , Male , Osteomyelitis/drug therapy , Osteomyelitis/pathology , Osteomyelitis/psychology , Quality of Life/psychology , Recurrence , Severity of Illness Index , Surveys and Questionnaires , Time Factors , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL